Sign inJoin waitlistJoin the waitlist

Theodore Gourdin

Associate Professor, Hematology & Oncology · Medical University of South Carolina College of Medicine

Credentials: · · · ·

History

Medical University of South Carolina College of Medicine
Present

Hematology and Medical Oncology
University of Maryland Program
2011–2014
Internal Medicine
Tulane University School of Medicine
2008–2011
University of South Carolina-Columbia
2004–2008

Research

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Journal for ImmunoTherapy of Cancer · 2020 · 68 citations
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
Seminars in Oncology · 2018 · 56 citations
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
Cancer · 2019 · 46 citations

GS
Guru Sonpavde
4 papers
Michael Lilly
4 papers
Ashkan Emadi
2 papers
James Gulley
2 papers
Maria Baer
2 papers
Petros Grivas
2 papers
VD
Vu Duong
2 papers
AC
Aaron Ciner
1 paper
Alexander Bray
1 paper · 1 as a fellow
Andrea Apolo
1 paper
Andrew Armstrong
1 paper
Andrew Hahn
1 paper · 1 as a fellow

Clinical trials

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027